Skip to main content Back to Top
Advertisement

5/2/2019

Cosyntropin Injection

Products Affected - Description

    • Cortrosyn lyophilized powder for injection, Amphastar, 0.25 mg, vial, 10 count, NDC 00548-5900-00
    • Cosyntropin lyophilized powder for injection, Mylan Institutional, 0.25 mg, vial, 10 count, NDC 67457-0227-02

Reason for the Shortage

    • Amphastar has Cortrosyn on shortage due to increased demand.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • Cosyntropin lyophilized powder for injection, Sandoz, 0.25 mg, vial, 10 count, NDC 00781-3440-95

Estimated Resupply Dates

    • Mylan Institutional has cosyntropin 0.25 mg vials on back order and the company estimates a release date of late-January 2020.
    • Amphastar has Cortrosyn 0.25 mg vials on intermittent back order with regular releases.

Updated

Updated May 2, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 22, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins